Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Announces Reverse Stock Split Ratio Ahead of Merger By: Investor Brand Network April 16, 2024 at 16:16 PM EDT QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company and Telix Pharmaceuticals Limited (ASX: TLX) (OTC: TLPPF), under which Telix will acquire QSAM. On April 15, 2024, the board of directors of QSAM unanimously approved a reverse stock split ratio of 1-for-2,000 that, once effective, every holder of common stock of the company shall receive one share of common stock for every 2,000 shares of common stock held (the “reverse stock split ”). On Feb. 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the board the discretion to adopt the ratio prior to the closing of the merger. To view the full press release, visit https://ibn.fm/b5gS2 About QSAM Biosciences Inc. QSAM Biosciences is developing next-generation nuclear medicines for the treatment of bone cancer. QSAM’s initial technology, 153 Sm-DOTMP, is a clinical-stage bone-targeting radiopharmaceutical originally developed by IsoTherapeutics Group LLC. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM About TinyGems TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.TinyGems.com Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer TinyGemsLos Angeles, CAwww.TinyGems.com310.299.1717 OfficeEditor@TinyGems.com TinyGems is powered by IBN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Announces Reverse Stock Split Ratio Ahead of Merger By: Investor Brand Network April 16, 2024 at 16:16 PM EDT QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company and Telix Pharmaceuticals Limited (ASX: TLX) (OTC: TLPPF), under which Telix will acquire QSAM. On April 15, 2024, the board of directors of QSAM unanimously approved a reverse stock split ratio of 1-for-2,000 that, once effective, every holder of common stock of the company shall receive one share of common stock for every 2,000 shares of common stock held (the “reverse stock split ”). On Feb. 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the board the discretion to adopt the ratio prior to the closing of the merger. To view the full press release, visit https://ibn.fm/b5gS2 About QSAM Biosciences Inc. QSAM Biosciences is developing next-generation nuclear medicines for the treatment of bone cancer. QSAM’s initial technology, 153 Sm-DOTMP, is a clinical-stage bone-targeting radiopharmaceutical originally developed by IsoTherapeutics Group LLC. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM About TinyGems TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.TinyGems.com Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer TinyGemsLos Angeles, CAwww.TinyGems.com310.299.1717 OfficeEditor@TinyGems.com TinyGems is powered by IBN
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company and Telix Pharmaceuticals Limited (ASX: TLX) (OTC: TLPPF), under which Telix will acquire QSAM. On April 15, 2024, the board of directors of QSAM unanimously approved a reverse stock split ratio of 1-for-2,000 that, once effective, every holder of common stock of the company shall receive one share of common stock for every 2,000 shares of common stock held (the “reverse stock split ”). On Feb. 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the board the discretion to adopt the ratio prior to the closing of the merger. To view the full press release, visit https://ibn.fm/b5gS2 About QSAM Biosciences Inc. QSAM Biosciences is developing next-generation nuclear medicines for the treatment of bone cancer. QSAM’s initial technology, 153 Sm-DOTMP, is a clinical-stage bone-targeting radiopharmaceutical originally developed by IsoTherapeutics Group LLC. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM About TinyGems TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.TinyGems.com Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer TinyGemsLos Angeles, CAwww.TinyGems.com310.299.1717 OfficeEditor@TinyGems.com TinyGems is powered by IBN